Medanta utilizes ultrasound-guided techniques for central line placements, ensuring precise and safe vascular access for patients.

TCR Alpha-Beta Depletion is an advanced technique used in haematopoietic stem cell transplantation (HSCT) to enhance the safety and efficacy of the procedure. T-cell receptors (TCRs) are proteins found on the surface of T cells, and the alpha-beta variant is the most common type. By selectively depleting T cells that express the alpha-beta TCR, this method aims to reduce the incidence of graft-versus-host disease (GVHD) while maintaining effective anti-infection and anti-tumour response responses. This technique enables the use of haploidentical, or half-match donors, increasing the pool of potential donors and making transplants more accessible.

An advanced medical facility equipped for minimally invasive vascular procedures, enhancing patient outcomes.

Donor Lymphocyte Infusion (DLI) is a valuable procedure in the post-transplant management of patients, supporting overall immune recovery, and fighting residual cancer cells and relapse. It involves infusing lymphocytes, a type of white blood cell, from the original stem cell donor into the recipient after the initial transplant. It represents a significant advancement in the fight against relapse in haematologic malignancies and post-transplant viral infections. In half-match transplants, it is also used to enhance immune function in cases where the recipient's immune recovery is insufficient. Medanta’s in-house Blood Bank helps safe donation, storage and infusion under one roof.

Chimeric Antigen Receptor (CAR) T cell therapy is a highly personalised, targeted and effective therapeutic approach for half-match transplantation and cancer. It involves genetically modifying a patient's own T cells to recognise and attack cancer cells, reducing damage to healthy cells and prolonging remission periods. Medanta’s state-of-the-art Blood Bank and diagnostic support mean the entire process can be done in-house. CAR T cell therapy has shown remarkable success in treating B-cell acute lymphoblastic leukaemia (B-ALL) and certain types of B-cell non-Hodgkin lymphoma (NHL). Research is ongoing to expand the use of CAR T cell therapy to treat various solid tumours. The therapy can have some side effects such as Cytokine Release Syndrome (CRS) and neurotoxicity.

CD45RA Depletion is a specialised technique used in allogeneic hematopoietic stem cell transplantation and cell therapy. CD45RA is a marker found on naïve T cells, which have not yet encountered antigens. Depleting these cells from donor grafts helps to reduce the risk of graft-versus-host disease (GVHD), a common complication where the donor's immune cells attack the recipient's tissues. This technique is beneficial for patients with high-risk leukaemia, aplastic anaemia, and inherited metabolic disorders. In the context of CAR-T cell therapy, CD45RA depletion can be employed to enhance the safety and efficacy of the treatment by minimising the risk of GVHD. It is also applied in virus-specific T-cell therapies to selectively expand memory T cells that can combat infections post-transplantation. A technical complex procedure, it requires sophisticated equipment and expertise, making it available only in specialized centers